Document Detail


Economic burden of venous thromboembolism in hospitalized patients.
MedLine Citation:
PMID:  19637948     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Venous thromboembolism, a condition that includes deep vein thrombosis and pulmonary embolism, is a significant medical problem that affects more than 1 million patients each year. In addition to the immense impact of venous thromboembolism on morbidity and mortality, the economic burden of the disease is considerable, costing the health care system in the United States more than $1.5 billion/year. The cost of managing an initial episode of deep vein thrombosis is estimated at $7712-10,804, and for an initial pulmonary embolism event $9566-16,644. Management of acute venous thromboembolism in patients with cancer costs more than $20,000. Although much of the costs of venous thromboembolism are associated with managing the acute event, there are also significant costs associated with its long-term complications such as recurrent venous thromboembolism, postthrombotic syndrome, and pulmonary hypertension. Data from numerous robust clinical trials have demonstrated that with appropriate prophylaxis, many of these venous thromboembolism events can be prevented in both surgical and medical patients. Even though the strong evidence supporting venous thromboembolism prophylaxis spans several decades, a number of large American and global registries have documented very poor use of appropriate venous thromboprophylaxis. Because of increasing regulatory requirements, hospitals nationwide are developing necessary documentation of appropriate venous thromboembolism prophylaxis programs for both surgical and medical patients. Hospitals and clinicians must have a firm understanding of not only the clinical impact but also the economic impact of failing to use appropriate prophylaxis and of the cost-effectiveness of different venous thromboprophylaxis methods.
Authors:
Paul P Dobesh
Related Documents :
6802028 - Arterial and venous dilation by nitroprusside and nitroglycerin--is there a difference?
11161568 - Expression of ephrinb2 identifies a stable genetic difference between arterial and veno...
9756098 - Identification of arterial and venous segments of blood vessels using alkaline phosphat...
14719178 - New anticoagulants.
3396288 - Hypothenar hammer syndrome with embolic occlusion of digital arteries.
10456398 - Ventricular outflow tracts after kawashima intraventricular rerouting for double outlet...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Pharmacotherapy     Volume:  29     ISSN:  1875-9114     ISO Abbreviation:  Pharmacotherapy     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-07-29     Completed Date:  2009-10-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  943-53     Citation Subset:  IM    
Affiliation:
College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198-6045, USA. pdobesh@unmc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials as Topic
Cost-Benefit Analysis / statistics & numerical data
Guideline Adherence / statistics & numerical data
Health Care Costs / statistics & numerical data*
Hospitalization
Humans
Hypertension, Pulmonary / complications,  prevention & control
Pharmaceutical Services
Postthrombotic Syndrome / complications,  prevention & control
Practice Guidelines as Topic
Professional Role
Recurrence / prevention & control
Risk Factors
Venous Thromboembolism / complications,  economics*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in h...
Next Document:  Overcoming drug resistance in patients with metastatic breast cancer.